

CASE 51752-US-PCT

|  |                                     |
|--|-------------------------------------|
| FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10         |                                     |
| <u>EV971833625 US</u><br>Express Mail Label Number | <u>7/24/2008</u><br>Date of Deposit |

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

ABIA CREASEY

INTERNATIONAL APPLICATION NO: PCT/US2005/009097

FILED: 17 MARCH 2005

U.S. APPLICATION NO: 10/593,135

35 USC §371 DATE: 18 SEPTEMBER 2006

FOR: TREATMENT OF SEVERE COMMUNITY-ACQUIRED PNEUMONIA  
BY ADMINISTRATION OF TISSUE FACTOR PATHWAY INHIBITOR  
(TFPI)

**MS: PCT**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

Applicant believes this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Leslie Fischer', is written over a horizontal line.

Leslie Fischer  
Attorney for Applicant  
Reg. No. 58,393

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-9308  
Encl.: 1449 forms (16 pages)  
168 References  
Date: 7/24/2008